Canada Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of geographies.   Canada’s biggest strengths are its diversity and openness—whether that is in health sciences or the culture itself Marina Vasiliou, Biogen Vasiliou…

Turkey There is perhaps no Turkish company in the healthcare sector that is more ambitious than Acıbadem. Not only has the private hospital group revolutionized healthcare in Turkey with its advanced facilities, but it has also pursued an ambitious internationalization campaign and even opened a world-class university, to boot.   We…

India The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports.  Given the tremendous importance of the Indian industry globally, this state therefore emerges as a pharmaceutical hub of global importance.   For…

Hong Kong Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious career in the US to bring in novel technologies to the city.   I feel happy that I have achieved my initial objectives: to bring international…

Turkey Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares his experience working for the largest biotech in the MENA region, Turkey’s important role within the global group, and his ambitious plans for the future.   “Having worked for leading Turkish companies for several years … I realized that…

Opinion This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms: global protests, drug pricing, and India’s “Modicare” milestone.    Protests First, the rash of protests unfolding across parts of the Middle East, Asia, and Latin America has piqued firms’ attention—not just…

Opinion Anthony Harrington of global investment banking and asset management firm Alantra outlines why healthcare and consulting communications companies are increasingly attractive targets for private equity.   The supply of PE money chasing fewer and fewer assets is only going to increase the attraction of healthcare communications and consulting firms to…

USA Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond.   To keep pace with the remarkable and continuing growth of gene therapy, FDA’s…

Sweden We recently analysed the contents of 20 interviews conducted with country managers at multinational pharma companies in Sweden and found some underlying words and themes present in the majority of the interviews (see above for the full wordcloud). This is an exclusive glimpse into what is currently at the top…

Brazil Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases.   This agreement establishes an exchange of know-how that will provide progress in public health policies in Brazil Patrice Matchaba, global head of corporate responsibility, Novartis…

Czech Republic The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’ While a number of promising steps have already been taken, it is far too soon to tell whether the Czechs…

UAE The UAE’s rapid economic growth over the last half-century has been accompanied by a surge in lifestyle diseases such as diabetes and obesity. Both public and private organizations are now stepping up to tackle this health and economic burden with expanded access to cutting-edge treatments, a greater focus on education…